News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
694,924 Results
Type
Article (39972)
Company Profile (333)
Press Release (654619)
Section
Business (206763)
Career Advice (2052)
Deals (35812)
Drug Delivery (88)
Drug Development (82130)
Employer Resources (172)
FDA (16156)
Job Trends (15116)
News (349435)
Policy (32761)
Tag
Academia (2550)
Alliances (49873)
Alzheimer's disease (1252)
Approvals (16088)
Artificial intelligence (133)
Bankruptcy (355)
Best Places to Work (11650)
Biotechnology (239)
Breast cancer (120)
Cancer (1086)
Cardiovascular disease (98)
Career advice (1709)
Cell therapy (236)
Clinical research (65269)
Collaboration (390)
Compensation (200)
COVID-19 (2553)
C-suite (97)
Data (1130)
Diabetes (152)
Diagnostics (6158)
Earnings (85837)
Employer resources (150)
Events (111831)
Executive appointments (313)
FDA (16692)
Funding (348)
Gene therapy (179)
GLP-1 (598)
Government (4364)
Healthcare (18748)
Infectious disease (2637)
Inflammatory bowel disease (108)
Interviews (325)
IPO (16527)
Job creations (3830)
Job search strategy (1463)
Layoffs (426)
Legal (7902)
Lung cancer (170)
Manufacturing (180)
Medical device (13190)
Medtech (13195)
Mergers & acquisitions (19354)
Metabolic disorders (405)
Neuroscience (1532)
NextGen Class of 2024 (6558)
Non-profit (4483)
Northern California (1480)
Obesity (230)
Opinion (196)
Patents (101)
People (57111)
Phase I (20309)
Phase II (28809)
Phase III (21362)
Pipeline (455)
Postmarket research (2563)
Preclinical (8635)
Radiopharmaceuticals (245)
Rare diseases (218)
Real estate (6013)
Regulatory (21769)
Research institute (2331)
Resumes & cover letters (354)
Southern California (1306)
Startups (3643)
United States (13560)
Vaccines (560)
Weight loss (172)
Date
Today (133)
Last 7 days (791)
Last 30 days (3758)
Last 365 days (36129)
2024 (33077)
2023 (40659)
2022 (51785)
2021 (56341)
2020 (54540)
2019 (46983)
2018 (35387)
2017 (32636)
2016 (32060)
2015 (38110)
2014 (32005)
2013 (26893)
2012 (29013)
2011 (29668)
2010 (27706)
Location
Africa (736)
Arizona (194)
Asia (38398)
Australia (6197)
California (3334)
Canada (1286)
China (253)
Colorado (145)
Connecticut (154)
Europe (82717)
Florida (459)
Georgia (116)
Illinois (341)
Indiana (197)
Kansas (96)
Maryland (583)
Massachusetts (2633)
Michigan (157)
Minnesota (273)
New Jersey (955)
New York (955)
North Carolina (742)
Northern California (1480)
Ohio (139)
Pennsylvania (843)
South America (1116)
Southern California (1306)
Texas (466)
Utah (90)
Washington State (363)
694,924 Results for "sutro biopharma inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Job Trends
BioSpace
Announces 2025 Best Places to Work in Biopharma
BioSpace
has named 50 biopharma companies to its 2025 Best Places to Work list, including Moderna and Sutro Biopharma, whose executives share what makes their organizations special.
November 12, 2024
·
6 min read
·
Angela Gabriel
Business
VGXI Inc. announces a strategic partnership with Sutro Biopharma Inc. to support growing clinical pipeline
VGXI, Inc. has entered into a strategic partnership with Sutro Biopharma, Inc. to support clinical production of luveltamab tazevibulin, abbreviated as “luvelta”, a novel Folate Receptor-α -targeting antibody-drug conjugate with the potential to address the unmet need in several FRα-expressing cancers.
June 3, 2024
·
4 min read
Press Releases
Sutro Biopharma Reports Third Quarter 2024 Financial Results and Business Highlights
November 14, 2024
·
10 min read
Business
Sutro Biopharma Reports First Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones
Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today reported its financial results for the first quarter of 2024, its recent business highlights, and a preview of select anticipated milestones.
May 13, 2024
·
10 min read
Press Releases
Sutro Biopharma Demonstrates Meaningful ADC Innovation with Five Presentations at the 15th Annual World ADC Conference
November 4, 2024
·
1 min read
Biotech Bay
Sutro Biopharma Announces Pricing of $75 Million Underwritten Offering
Sutro Biopharma, Inc., a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates, announced the pricing of an underwritten offering of 14,478,764 shares of its common stock at a price of $5.18 per share.
April 2, 2024
·
5 min read
Biotech Bay
Sutro Biopharma Announces Initiation of Randomized Portion (Part 2) of REFRαME-O1 Trial
Sutro Biopharma, Inc. today announced that the randomized portion (Part 2) of REFRαME-O1, the registration-directed trial of luveltamab tazevibulin (luvelta) in platinum-resistant ovarian cancer (PROC), is now open for enrollment, and the planned 50 patients in Part 1 of the trial have been enrolled.
April 30, 2024
·
5 min read
Press Releases
Sutro Biopharma Announces Initiation of the Registration-enabling REFRαME-P1 Trial with Luvelta for Pediatric Patients with CBF/GLIS AML
November 4, 2024
·
7 min read
News
Sutro Biopharma Highlights Next-Generation ADC Innovation and Near-term Pipeline at Research Forum
October 10, 2024
·
7 min read
Biotech Bay
Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors
Ipsen and Sutro Biopharma announced an exclusive global licensing agreement for STRO-003.
April 2, 2024
·
10 min read
1 of 69,493
Next
